Loading organizations...
AtaiBeckley is a clinical-stage biopharmaceutical company based in New York, New York, that develops rapid-acting psychedelic treatments and related therapies for difficult-to-treat mental health conditions. The publicly traded entity operates on the NASDAQ under the ticker ATAI following a strategic business combination that fully internalized Beckley Psytech's clinical assets. Prior to the consolidation, the predecessor organization executed a $50 million strategic investment in January 2024 to acquire an initial one-third ownership stake in its partner. The combined enterprise's clinical pipeline and corporate operations are managed by a leadership team that includes Chief Executive Officer Dr. Srinivas Rao, Chief Medical Officer Kevin Craig, and Chief Scientific Officer Glenn Short. AtaiBeckley was officially formed in 2025 through the merger of Beckley Psytech and atai Life Sciences, an entity which was originally founded in 2018 by Christian Angermayer.
AtaiBeckley has raised $322.0M across 4 funding rounds.
AtaiBeckley has raised $322.0M in total across 4 funding rounds.
AtaiBeckley is a clinical-stage biopharmaceutical company, not a technology company in the traditional software sense, focused on developing effective, rapid-acting, and convenient treatments for mental health conditions.[1][2] It addresses the massive unmet need in mental health, where over one billion people worldwide live with such conditions, most lack access to effective care, and global economic costs are projected to hit $5 trillion by 2030.[1] The company serves patients with limited treatment options through a pipeline of patient-first, evidence-based therapies, particularly leveraging psychedelic-inspired candidates, and recently achieved a milestone by being added to the Nasdaq Biotechnology Index (NBI).[2]
Formed via a $390 million merger of two psychedelic medicine pioneers, AtaiBeckley combines expertise in drug development, healthcare, and commercialization to transform outcomes in this space.[1][3] Its growth momentum includes a robust pipeline targeting high-need areas and public market recognition, positioning it for scaled impact.[2][3]
AtaiBeckley emerged from a landmark $390 million merger between atai Life Sciences and Beckley Psytech, two pioneers in psychedelic medicines, which completed recently to consolidate their pipelines for mental health treatments.[3] This union builds on atai's model of incubating and advancing novel therapies and Beckley's focus on rapid-acting psychedelics, creating a unified entity with deep expertise in clinical-stage biopharma.[1][3]
The idea stems from the urgent need to overhaul mental health care, where traditional options fall short for over a billion affected individuals.[1] Early traction came from the merging entities' parallel advancements in psychedelic candidates, culminating in this deal to accelerate development and commercialization under a shared mission.[3] Key leadership includes a diverse team of drug development and healthcare experts driving the effort.[1]
AtaiBeckley rides the surging wave of psychedelic and neuroscience biotech, harnessing repurposed compounds for mental health amid rising awareness of conditions affecting one billion people.[1][3] Timing is ideal as regulatory shifts, post-pandemic mental health crises, and economic projections ($5 trillion by 2030) create tailwinds for innovative therapies over legacy treatments.[1]
Market forces like limited access to care favor its rapid-acting pipeline, influencing the ecosystem by validating psychedelics in clinical stages and accelerating mergers in the space.[3] As a Nasdaq-listed player, it bridges biotech with broader tech-health intersections, drawing investment into evidence-based mental health innovation.[2]
AtaiBeckley is poised to advance its pipeline through key clinical readouts and potential approvals, capitalizing on merger synergies for faster commercialization.[3] Trends like AI-aided drug discovery, psychedelic normalization, and global mental health funding will shape its path, potentially expanding into new therapeutic areas.[1]
Its influence may evolve from pipeline consolidator to market leader, redefining treatments and inspiring ecosystem-wide breakthroughs—transforming the one-billion-person challenge into scalable solutions, as its mission promises.[1][2]
AtaiBeckley has raised $322.0M across 4 funding rounds. Most recently, it raised $160.0M Series D in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2021 | $160M Series D | — | Ambridge Capital, Brkfst Club, Calm/Storm Ventures, DN Capital, Endeavor Venture Funds, FJ Labs, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Raine Ventures, GIL Penchina, Thiel Capital, What IF Ventures, Akshay Sriprasad, Eytan Elbaz | Announced |
| Nov 1, 2020 | $93M Series C | — | Calm/Storm Ventures, Endeavor Venture Funds, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Thiel Capital, What IF Ventures, Akshay Sriprasad | Announced |
| Feb 1, 2019 | $43M Series B | — | Aglae Ventures | Announced |
| Oct 1, 2018 | $26M Series A | — | Adjacent, Archetype, Asylum Ventures, Galaxy Digital, Initialized Capital, Kleiner Perkins, Otherwise Fund | Announced |
AtaiBeckley has raised $322.0M in total across 4 funding rounds.
AtaiBeckley's investors include Ambridge Capital, Brkfst Club, Calm/Storm Ventures, DN Capital, Endeavor Venture Funds, FJ Labs, Founders Fund, Future Ventures, Negev Capital, Presight Capital, PsyMed Ventures, Raine Ventures.